Quo vadis Dialysis Membrane?
Abstract
Abstract: The development of dialysis membranes is closely related to the development of dialysis as a routine therapy for patients with kidney failure. Without having membranes and dialyzers available as commodity products, the treatment of more than 1 million uremic patients worldwide would be impossible. Several transition periods can be identified: a change in membrane geometry from flat sheet to capillaries, a shift in market appreciation from cellulose to synthetic polymers, and from low-flux to high-flux dialyzers. This shift is supported by the notion that convective therapies using high-flux membranes allow the removal of large-molecular-weight solutes. From a historical background, three eras of perception can be identified for both membrane and dialysis development. First, the period of survival when nephrologists had to focus on techniques for blood access and availability of membranes. Second, the period of issues dedicated to rather specific features of membranes and dialysis therapy such as dose of dialysis, reuse, sterilization, and membrane biocompatibility. And third, the period of quality tops this sequence with a complicated approach: the principal area of interest from the medical community has switched to issues such as quality of life, morbidity, mortality, therapy standards, and cost-effectiveness. New membrane developments should focus on this situation.
REFERENCES
- 1 Clinica 1998;829:5.
- 2 Lysaght M. Evolution of hemodialysis membranes. Contrib Nephrol 1997; 113: 1–10.
- 3 Ledebo I. Principles and practice of hemofiltration and hemodiafiltration. Artif Organs 1998; 22: 20–5.
- 4 Feldman H, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996; 7: 523–35.
- 5 Kapoian T, Sherman RA. A brief history of vascular access for hemodialysis: an unfinished story. Semin Nephrol 1997; 17: 239–45.
- 6 Petitclerc T. Estimation of mass transfer through a hemodialyzer: theoretical approach and clinical applications. Artif Organs 1998; 22: 601–7.
- 7 Dolovich J, Bell B. Allergy to products of ethylene oxide gas. J Allergy Clin Immunol 1978; 62: 30–2.
- 8 Daugirdas J, Ing T, Roxe D. Severe anaphylactoid reactions to cuprammonium hemodialyzers. Arch Intern Med 1985; 145: 489–94.
- 9 Bommer J, Barth H, Wilhelms O, Schindele H. Anaphylactoid reactions in dialysis patients: role of ethylene oxide. Lancet 1985; 2: 1382.
- 10 Röckel A, Hertel J, Wahn U, Perschel T, Thiel C, Abdelhamid S, Fleigel P, Walb D. Ethylene oxide and hypersensitivity reactions in patients on hemodialysis. Kidney Int 1988; 33(suppl 24): 62–7.
- 11 Kaplow L, Goffinet J. Profound neutropenia during the early phase of hemodialysis. JAMA 1968; 203: 133–5.
- 12 Craddock P, Fehr J, Dalmasso A, Brigham K, Jacob H. Hemodialysis leucopenia: pulmonary vascular leukostasis resulting from complement activation of dialyzer cellophane membranes. J Clin Invest 1977; 59: 879–88.
- 13 Craddock PR, Fehr J, Brighman KL. Complement and leukocyte-mediated pulmonary dysfunctin in hemodialysis. N Engl J Med 1977; 296: 769–74.
- 14 Chenoweth D, Cheung A, Henderson L. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983; 24: 764–9.
- 15 Stegmayr B, Esbensen K, Gutierrez A, Lundberg L, Lielsen B, Stroemsaeter C, Wehle B. Granulocyte elastase, β-thromboglobulin and C3d during acetate or bicarbonate hemodialysis for Hemophan compared to a cellulose acetate membrane. Int J Artif Organs 1992; 15: 10–8.
- 16 Sultan Y, London G, Goldfarb B, Toulon R, Marchais S. Activation of platelets, coagulation and fibrinolysis in patients on long term hemodialysis: influence of Cuprophan and polyacrylonitrile membranes. Nephrol Dial Transplant 1990; 5: 362–8.
- 17 Dinarello C, Lonnemann G, Bingel M, Koch K, Shaldon S. Biological consequences of monocyte activation during hemodialysis. Contrib Nephrol 1987; 59: 1–9.
- 18 Lonnemann G, Koch K, Shaldon S, Dinarello C. Studies on the ability of hemodialysis membranes to induce, bind and clear human interleukin-1. J Lab Clin Med 1988; 112: 76–86.
- 19
Fick A.
Über Diffusion.
Ann Phys Chem
1855; 94: 59–86.
10.1002/andp.18551700105 Google Scholar
- 20 Shaldon S, Vienken J. Biocompatibility: is it a relevant consideration for today's hemodialysis? Int J Artif Organs 1996; 19: 201–14.
- 21 Vanholder R, De Vriese A, Lamiere N. The role of dialyzer biocompatibility in acute renal failure. Blood Purif 2000; 18: 1–12.
- 22 Von Sengbusch G, Bowry S, Vienken J. Focusing on membranes. Artif Organs 1993; 17: 244–53.
- 23 Vienken J, Diamantoglou M, Hahn C, Kamusewitz H, Paul D. Considerations on developmental effects of biocompatible dialysis membranes. Artif Organs 1995; 19: 398–406.
- 24 Streicher E, Schneider H. Polysulfone membrane mimicking human glomerular basement membrane. Lancet 1983; 2: 1136.
- 25 Singer S, Nicholson G. The fluid mosaic model of the structure of cell membranes. Science 1972; 175: 720–31.
- 26 Diamantoglou M, Lemke H, Vienken J. Cellulose esters as membrane materials for hemodialysis. Int J Artif Organs 1994; 17: 385–91.
- 27
Diamantoglou M,
Platz J,
Vienken J.
Cellulose carbamates and derivatives as membrane materials for hemodialysis.
Artif Organs
1995; 23: 15–23.DOI: 10.1046/j.1525-1594.1999.06272.x
10.1046/j.1525-1594.1999.06272.x Google Scholar
- 28 Bosch T, Schmidt B, Samtleben W, Gurland H. Biocompatibility and clinical performance of a new modified cellulose membrane. Clin Nephrol 1986; 26(suppl): 22–9.
- 29 Green D, Antwiler G, Montcrief J, Decherd J, Popovich R. Measurement of the transmittance coefficient spectrum of Cuprophan and RP69 membranes: application of middle molecule removal via ultrafiltration. Trans ASAIO 1976; 22: 627–35.
- 30 Takesawa S, Satoh S, Hidai H, Seikiguchi M, Sakai K. Degradation by gamma irradiation of regenerated cellulose membranes for clinical dialysis. Trans ASAIO 1987; 23: 584–7.
- 31 Bommer J, Miltenburger H, Hoerner V, Kilian S. Cytotoxicity of gamma ray sterilized dialysis devices (abstract). J Am Soc Nephrol 1994; 5: 408.
- 32 Takesawa S, Ohmi S, Konno Y, Seikiguchi M, Shitaokoshi S, Takahashi T, Hidai H, Sakai K. Varying methods of sterilization and their effects on the structure and permeability of dialysis membranes. Nephrol Dial Transplant 1987; 1: 254–7.
- 33 Depner T, Optimizing the treatment of the dialysis patient: a painful lesson. Semin Nephrol 1997;17:285–97.
- 34 Dorhout Mees E. Adequacy of dialysis revisited. Int J Artif Organs 1999; 22: 8–10.
- 35 Levin N, Eknoyan G, Pipp M. National Kidney Foundation: Dialysis Outcome Quality Initiative—Development of methodology for clinical practice guidelines. Nephrol Dial Transplant 1997; 12: 2060–3.
- 36 Floege J, Koch K. β2-m associated amyloidosis and therapy with high flux hemodialysis membranes. Clin Nephrol 1994; 42(suppl 1): 52–6.
- 37 Floege J, Schaeffer J, Koch K, Shaldon S. Dialysis related amyloidosis: a disease of chronic retention and inflammation. Kidney Int 1992; 42(suppl 38): 78–85.
- 38 Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T. Switch from conventional to high flux membrane reduces the risk of carpel tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–101.
- 39 Zingraff J, Drueke T. Can the nephrologist prevent dialysis-related amyloidosis? Am J Kidney Dis 1991; 18: 1–11.
- 40 David S, Bottalico D, Tagliavini D, Mandolfo S, Scanziani R, Cambi V. Behaviour of β2-m removal with different dialysis schedules. Nephrol Dial Transplant 1998; 13(suppl 6): 49–54.
- 41 Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999; 55: 286–93.DOI: 10.1046/j.1523-1755.1999.00236.x
- 42 Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch K, Floege J. β2-m associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int 1997; 52: 1077–83.
- 43 Baz M, Durand C, Ragon A, Jaber K, Andrieu D, Merzouk T, Purgus R, Olmer M, Reynier J, Berland Y. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681–5.
- 44 Collins A, Keshaviah P, Ilstrup K, Shapiro F. Clinical comparison of hemodialysis and hemofiltration. Kidney Int 1985; 28(suppl 17): 18–22.
- 45 Altieri P, Sorba G, Bolsaco P. Online predilution hemofiltration versus ultrapure highflux hemodialysis: a multicenter perspective study in 23 patients. Blood Purif 1997; 15: 169–81.
- 46 Maggiore Q, Pizzarelli F, Dattolo P, Maggiore U, Cerrai T. Cardiovascular stability during hemodialysis, hemofiltration and hemodiafiltration. Nephrol Dial Transplant 2000; 15(suppl 1): 68–73.
- 47 Hakim R, Wingard R, Parker R. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331: 1338–42.
- 48 Schiffl H, Lang S, König A, Strasser T, Haider M, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344: 570–2.
- 49 Jörres A, Gahl G, Dobis C, Polenakovic M, Cakalorski K, Rutkowski B, Kisienicka E, Krieter D, Rumpf K, Guenther C, Gaus W, Hoegel J. Hemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomized multicenter study. Lancet 1999; 354: 1337–41.
- 50 Vanholder R, De Vriese A, Lameire N. The role of dialyzer biocompatibility in acute renal failure. Blood Purif 2000; 18: 1–12.
- 51 Woods F, Nandakumar M. Improved outcome for hemodialysis patients treated with high flux membranes. Nephrol Dial Transplant 2000; 15(suppl 1): 36–42.
- 52 Pork FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37: 276–286.
- 53 Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with Cuprophan. Kidney Int 1991; 40: 714–9.
- 54 Cheung A. Quantification of dialysis. Blood Purif 1994; 12: 42–53.
- 55 Henderson L. Future developments in the treatment of end-stage-renal disease: a North American perspective. Am J Kidney Dis 2000; 35(suppl 1): 106–16.